Increased incidence of metachronous gastric neoplasm after endoscopic resection in patients with synchronous gastric neoplasm

Ga-Yeong Shin 1, Hye Jin Cho 1, Jae Myung Park 1,2*, Chul-Hyun Lim 1, Yu Kyung Cho 1 and Myung-Gyu Choi 1,2

Abstract

Background: Recurrence risk is a major concern after endoscopic resection (ER) of gastric neoplasms. This study was to compare metachronous risk in patients with and without synchronous neoplasms after complete ER.

Methods: After ER for gastric neoplasms, patients were divided into those with and without synchronous neoplasm. The metachronous risk of gastric neoplasms was compared between the two groups.

Results: After ER of 678 cancers and 891 adenomas, synchronous neoplasm was found in 11.8% of cancers and 11.4% of adenomas. In the multiple (n = 182) and the single group (n = 1387), metachronous neoplasms occurred in 18.1 and 8.6%, respectively (HR 2.40; 95% CI, 1.62–3.34). When the pathology of the recurred lesion was limited to cancer, metachronous risk was also significantly higher in the multiple than in the single group (HR, 2.2; 95% CI, 1.17–3.85). In the recurred pathology of the multiple group, cancer development was frequently observed in patients with cancer compared to those with only adenomas in the synchronous lesion (67.0% vs. 13.0%, respectively; P = 0.023).

Conclusions: This study demonstrated that metachronous risk was significantly higher in patients with synchronous gastric neoplasms after ER. Therefore, meticulous examination is important in patients with synchronous neoplasm.

Keywords: Stomach neoplasms, Endoscopy, Recurrence, Endoscopic mucosal resection

Background

Gastric cancer is the fifth most common cancer worldwide, comprising 6.8% of total cancer incidence, and the third leading cause of cancer death, making up 8.8% of total cancer deaths [1]. Therefore, early detection of gastric cancer is important for a better prognosis [2]. In Korea, a screening program has allowed detection of gastric cancer at an early stage, resulting in a reduction in mortality [3].

Endoscopic resection (ER) including endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) is now widely performed and accepted as an effective treatment option for early gastric cancer (EGC) that poses a low risk of lymph node metastasis [4]. Guidelines also recommend removal of adenomas as well as EGCs for diagnosis and treatment [5, 6], because adenomas are precancerous lesions [7] but initially
noninvasive adenomas can advance to invasive adenocarcinoma even after ER in 4 to 30% of cases [8, 9].

Although ER has many advantages including quality of life, cost-effectiveness, and hospital stay compared to surgery, the development of metachronous cancer in the remnant gastric mucosa is one of its major problems [10, 11]. The incidence of metachronous cancer after ER ranges between 2.7 and 14% over 2.2 to 7 years of follow-up [12–14]. Many studies have reported risk factors for metachronous cancer after ER, which included the patient’s age, multiple EGCs, persistent Helicobacter pylori infection [13–15]. However, these studies were conducted after removal of EGCs only, not including adenomas.

Considering our previous study report that the incidence of post-ER metachronous gastric cancer was not significantly different after removal of adenomas and EGCs [16], the metachronous risk of gastric adenoma after ER should be investigated as well. Furthermore, the incidence of metachronous neoplasm is not well documented in patients with synchronous gastric neoplasms after removal of lesions, although synchronous gastric cancer has been reported at rates of 5–11% in the resected stomach after ER [17].

In this study, we investigated the incidence of metachronous gastric neoplasm between patients with and without synchronous gastric neoplasms. We also compared the outcomes of metachronous neoplasm according to the histological types of synchronous neoplasms.

**Methods**

**Patients**

This study was retrospectively performed in patients who underwent endoscopic resection (ER) of gastric neoplasms between January 1999 and December 2015 at Seoul St. Mary’s Hospital in Seoul, Korea. We excluded patients with a history of gastric cancer surgery, additional gastrectomy after non-curative or incomplete ER, no diagnosis of adenoma or EGC after ER, recurrence at previous ER site, and follow-up of less than 1 year. We retrieved medical records which included patients’ demographics, pathology results, ER modalities, infection status of *H. pylori*, gastric atrophy, and the development of metachronous neoplasm. In our study, pathological diagnoses were based on Vienna classification [18, 19]: adenoma group contained LGD as category 3, HGD as category 4.1, and non-invasive carcinoma as category 4.2, suspicion of invasive carcinoma as category 4.3, and invasive neoplasia as category 5 belong to the carcinoma group. We defined neoplasms as synchronous when the lesions detected by endoscopic examination within 12 months from the time of ER. Patients were divided into two groups by the absence (the single group) or presence (the multiple group) of synchronous lesions. Patients in the multiple group were further divided into two subgroups according to having or not having cancer on the resected specimen histology. This study was approved by the Institutional Review Board of the study institution (IRB number K15RISIo194).

**Endoscopic resection and follow-up**

Gastric atrophy was defined with endoscopic examination and categorized as closed or open type using Kimura–Takemoto classification [20]. The lesion was demarcated after spraying indigo carmine solution, followed by saline injection and mucosal incision. A snare was used during EMR, while a Hook knife (Olympus Medical Systems Co. Ltd., Tokyo, Japan) was used during ESD. Electronic thermocoagulation was then applied simultaneously. Every procedure was undergone by endoscopists who had performed these more than 5 years.

After ER, all patients underwent follow-up endoscopies within 6 months, at 12 months, and yearly thereafter. Suspicious mucosal lesions were biopsied and histologically evaluated in follow-up endoscopies. Follow-up endoscopies were done by the same endoscopists who had executed therapeutic procedures. Metachronous recurrence was defined as a new neoplasm that developed more than 1 year after ER.

**Determination of *H. pylori* status**

*Helicobacter pylori* infection was confirmed with either a positive result on a rapid urease test (CLO test; Ballard Medical Products, Draper, Utah) or Warthin–Starry silver staining at the time of ER. After diagnosis, we used a 7-day regimen with a proton pump inhibitor, 1 g of amoxicillin and 500 mg of clarithromycin twice daily as a first-line eradication. If this regimen failed, a second-line prescription containing a proton pump inhibitor bid, 250 mg of metronidazole tid, 500 mg of tetracycline qid, and 240 mg of bismuth qid were administered for 14 days. A 13C-urea breath test (Helifinder; Medichems, Seoul, South Korea) was performed to find out whether eradication was successful at least 4 weeks after the treatment.

**Outcome measurements**

Primary and secondary outcomes were the development of gastric neoplasm and gastric cancer after ER, respectively. Censored time was the day of last follow-up examination. Recurrence period was determined as the interval from the treatment to the last follow-up.

**Statistical analysis**

Continuous data are presented as mean ± standard deviation or median (interquartile range), and categorical data as quantities and proportions. Continuous variables were compared using two-sample independent *t* test or
Mann–Whitney U test for numerical variables, and nominal variables using Chi-square test or Fisher’s exact test. We performed the Kaplan–Meier method to analyze the cumulative incidence of gastric cancer and neoplasia after ER, and log-rank test for two-group comparison. We used Cox proportional hazard models for analyses of the independent association between pathologic results of gastric neoplasia and recurrence of metachronous tumor. Age, sex, presence of synchronous neoplasm, endoscopic atrophy, pathology of resected specimen, and *H. pylori* status were chosen as covariates for multivariate analysis. Statistical analysis was performed using SAS version 9.3 (SAS Institute, Cary, NC, USA) with a significance level of *P* < 0.05.

**Results**

**Study population**

A total of 2080 patients underwent ER for gastric neoplasms from January 1999 to December 2015. Of these patients, 511 patients were excluded due to additional gastrectomy for non-curative ER (*n* = 25), recurrence at previous ER site (*n* = 15), no diagnosis of adenoma or EGC (*n* = 188) and follow-up of less than 1 year (*n* = 283). After exclusion, 1569 patients were analyzed in the study (Fig. 1).

The baseline characteristics of the patients are summarized in Table 1. ER was performed in patients with EGCs (*n* = 678, 43.2%) and adenomas (*n* = 891, 56.8%). The median follow-up period was 30 months (range, 12–161 months). Among them, 1387 (88.4%) were in the single group and 182 patients (11.6%) were in the multiple group. The median age was higher in the multiple than the single group (66.1 ± 8.0 vs. 63.2 ± 9.4 years, *P* < 0.001). However, there were no significant differences in other baseline characteristics including sex, proportion of initial pathology, location, invasion depth of tumors, incidence of *H. pylori* infection, and follow-up duration between the two groups (Table 1). In the single group, cancer pathology included differentiated cancer (*n* = 576, 41.5%) and undifferentiated cancer (*n* = 22, 1.6%). In the multiple group, cancer pathology included differentiated cancer (*n* = 80, 44.0%) and no undifferentiated cancer (*n* = 0, 0%).

**Incidence of metachronous neoplasm after ER**

During the follow-up period, metachronous recurrence was found in 152 patients (9.7%). All metachronous neoplasms were successfully treated by ER without additional treatment. In the single group, 119 patients (8.6%) had metachronous neoplasms with pathologies revealed as 65 adenomas (4.6%) and 54 cancers (3.9%). In the multiple group, metachronous neoplasms were found in 33 patients (18.1%) with pathologies revealed as 19 adenomas (10.4%) and 14 cancers (7.7%). Kaplan–Meier analysis of the cumulative incidence of metachronous neoplasm and cancers after ER showed a significant difference between the two groups (*P* < 0.01, log-rank test). (Fig. 2a and b). Table 2 shows the results of univariate and multivariate Cox proportional hazards models for the risk of metachronous gastric neoplasm.

On univariate analysis, multiple group (hazard ratio [HR], 2.32; 95% confidence interval [CI], 1.54–3.40) and persistent *H. pylori* infection compared to eradicated *H. pylori* infection (hazard ratio [HR], 1.64; 95% confidence
interval [CI], 1.04–2.58) were significant factors associated with the development of metachronous neoplasm. In addition, the multiple group was also a significant factor associated with the development of metachronous cancer (HR, 2.2; 95% CI, 1.19–3.88) However, the pathology of the resected specimen, severity of atrophic gastritis, and patient demographics were not significant factors for metachronous neoplasia. Multivariate Cox analysis shows that the multiple group (hazard ratio [HR], 2.40; 95% confidence interval [CI], 1.62–3.34) and persistent *H. pylori* infection (hazard ratio [HR], 1.71; 95% confidence interval [CI], 1.09–2.61) were significant.

### Table 1 Baseline characteristics in single and multiple groups

|                         | Total (N=1569) | Single group (n=1387) | Multiple group (n=182) | P     |
|-------------------------|----------------|------------------------|------------------------|-------|
| Age (mean ± SD)         | 63.2 ± 9.3     | 63.2 ± 9.4             | 66.1 ± 8.0             | < 0.001 |
| Male, n (%)             | 1103 (70.3%)   | 965 (69.9%)            | 138 (75.8%)            | 0.078  |
| Cancer, n (%)           | 678 (43.2%)    | 598 (43.1%)            | 80 (44.0%)             | 0.829  |
| Endoscopic atrophy      |                |                        |                        | 0.016  |
| Open type               | 895 (57.0%)    | 776 (56.0%)            | 119 (65.4%)            |       |
| Closed type             | 674 (43.0%)    | 611 (44.1%)            | 63 (34.6%)             |       |
| Tumor location          |                |                        |                        | 0.545  |
| Upper, n (%)            | 73 (4.7%)      | 66 (4.7%)              | 7 (3.9%)               |       |
| Middle, n (%)           | 491 (31.3%)    | 428 (30.9%)            | 63 (34.6%)             |       |
| Lower, n (%)            | 1005 (64.1%)   | 893 (64.4%)            | 112 (61.5%)            |       |
| Macroscopic type        |                |                        |                        | 0.384  |
| Depressed, n (%)        | 222 (14.1%)    | 204 (14.6%)            | 18 (10.7%)             |       |
| Lesion diameter, mm (mean ± SD) | 14.5 ± 10.8 | 14.5 ± 11              | 15 ± 9.5               | 0.496  |
| Depth of invasion       |                |                        |                        | 0.291  |
| Mucosa, n (%)           | 1522 (9.1%)    | 1343 (96.8%)           | 179 (98.4%)            |       |
| Submucosa, n (%)        | 47 (3.0%)      | 44 (3.2%)              | 3 (1.7%)               |       |
| *Helicobacter pylori* infection, n (%) | 793/1501 (52.8%) | 701/1323 (53.0%) | 92/178 (51.7%) | 0.714  |
| Persistent              | 261 (36.3%)    | 227 (17.2%)            | 34 (19.1%)             |       |
| Eradicated              | 532 (68.4%)    | 474 (35.8%)            | 58 (32.6%)             |       |
| Negative                | 708 (95.3%)    | 622 (47.0%)            | 86 (48.3%)             |       |
| Follow-up, months (median, range) | 30 (12–161) | 30 (12–161)           | 25 (12–112)            | 0.261  |

*68 patients were not examined*
factors associated with the development of metachronous neoplasia.

Characteristics of metachronous neoplasm in the single and the multiple group
The clinicopathological characteristics of metachronous gastric neoplasm are summarized in Table 3. There was a significant difference in patient age and no significant difference in sex, pathological characteristics, infection and eradication rate of *H. pylori*, and interval time to detect metachronous neoplasm (Table 3).

Table 2 Cox proportional hazard models for the cumulative incidence of metachronous neoplasm after endoscopic resection in patients with and without synchronous neoplasms

|                      | Univariate analysis |          |          |          | Multivariate analysis |          |          |
|----------------------|---------------------|----------|----------|----------|-----------------------|----------|----------|
|                      | HR                  | 95% CI   | P        | HR       | 95% CI                | P        |
| Age, years           | 1.02                | 0.99–1.04| 0.984    | 1.02     | 0.99–1.04             | 0.984    |
| Male vs. female      | 1.12                | 0.82–1.72| 0.380    | 1.12     | 0.82–1.72             | 0.380    |
| Multiple vs. Single group | 2.32              | 1.54–3.40| < 0.001  | 2.40     | 1.62–3.34             | < 0.001  |
| Open vs. Closed type of atrophic gastritis | 1.20 | 0.86–1.70 | 0.288 | 1.20 | 0.86–1.70 | 0.288 |
| EGC vs. Adenoma      | 1.01                | 0.73–1.40| 0.952    | 1.01     | 0.73–1.40             | 0.952    |

*Helicobacter pylori*^a^  
Eradicated  
Positive 1.15 | 0.79–1.68 | 0.466  
Persistent 1.64 | 1.04–2.58 | 0.032  
1.71 | 1.09–2.61 | 0.002^a^  

^68 patients were not examined  
Abbreviations: HR hazard ratio, CI confidence interval, EGC early gastric cancer

The incidence and characteristics of metachronous neoplasm in the multiple group
To compare the incidence of metachronous neoplasm depending on pathology, the multiple group was further divided into patients with and without cancer in multiple lesions. There were no significant differences in patients’ characteristics, endoscopic findings, and *H. pylori*

Table 3 Clinicopathologic characteristics of metachronous neoplasm after endoscopic resection of gastric neoplasm between the single and the multiple group

|                      | Single group (n = 119) |          |          | Multiple group (n = 33) |          |          | P        |
|----------------------|------------------------|----------|----------|------------------------|----------|----------|----------|
| Age (median, range)  | 63 (44–83)             |          |          | 66 (48–81)             |          |          | 0.035    |
| Gender               |                        |          |          |                        |          |          | 0.965    |
| Male, n (%)          | 87 (73.1%)             |          |          | 24 (72.7%)             |          |          |         |
| Female, n (%)        | 32 (26.9%)             |          |          | 9 (27.3%)              |          |          |         |
| Cancer, n (%)        | 62 (52.1%)             |          |          | 17 (51.5%)             |          |          | 0.952    |
| Tumor location       |                        |          |          |                        |          |          | 0.414    |
| Upper, n (%)         | 6 (5.0%)               |          |          | 0 (0%)                 |          |          |         |
| Middle, n (%)        | 36 (30.3%)             |          |          | 10 (30.3%)             |          |          |         |
| Lower, n (%)         | 77 (64.7%)             |          |          | 23 (69.7%)             |          |          |         |
| Macroscopic type     |                        |          |          |                        |          |          | 0.197    |
| Depressed, n (%)     | 13 (10.9%)             |          |          | 0 (0%)                 |          |          |         |
| Diameter, cm (median, range) | 12 (2–65) |          |          | 14 (1–36)             |          |          | 0.411    |
| Depth of invasion    |                        |          |          |                        |          |          | 0.954    |
| Mucosa, n (%)        | 114 (95.8%)            |          |          | 32 (97%)               |          |          |         |
| Submucosa, n (%)     | 5 (4.2%)               |          |          | 1 (3.0%)               |          |          |         |
| *Helicobacter pylori* |                        |          |          |                        |          |          |         |
| Positive rate, n (%) | 61 (51.3%)             |          |          | 14 (42.4%)             |          |          | 0.579    |
| Eradication rate, n (%) | 36 (30.5%) |          |          | 8 (24.2%)             |          |          | 0.512    |
| Time to recur (months), (median and range) | 47 (12–155) |          |          | 24 (12–100) |          |          | 0.451    |
infection between the cancer-included and the adenoma-only groups. Metachronous neoplasm was found in 18 (18%) patients in the cancer-included group and 15 (18%) patients in the only adenomas group (Fig. 3), which was not statistically significant \( (P = 0.984, \text{log-rank test; Fig. 4a}) \). However, the proportion of recurrent pathology was different between the cancer-included and the only adenomas subgroups in the multiple group. Among metachronous neoplasms \( (n = 18) \) of the cancer-included subgroup, six adenomas (33%, five low grade and one high grade) and 12 differentiated cancers (67.0%) were found during the follow-up period. Among metachronous neoplasms \( (n = 15) \) of the only adenomas subgroup, 13 adenomas (87%, ten low grade and three high grade) and two differentiated cancers (13.0%) were found. The cumulative incidence of metachronous cancers after ER showed a significant difference between the two subgroups \( (P = 0.023, \text{log-rank test; Fig. 4b}) \).

**Discussion**

In our study, we compared the risk of metachronous recurrence between patients with and without synchronous gastric neoplasm after ER. Among all patients with gastric neoplasms, 11.6% had synchronous lesions. Patients with synchronous gastric neoplasms had about two-fold higher recurrence risk of neoplasms compared to those without synchronous lesions. Among patients with synchronous neoplasms, recurrence rate was not significantly different between patients with and without cancer. However, cancer recurrence rate was higher in patients with cancers than those with only adenomas.

Metachronous gastric cancer from remnant stomach after ER has been an important problem, although ER can preserve the stomach and contribute to a better quality of life compared to surgery [10, 11]. There have been many studies evaluating the risk factors of metachronous gastric cancer after ER. Previous studies usually focused on metachronous recurrence after ER of EGC and incidence of metachronous cancer not including adenomas. In this study, we investigated the recurrence of adenoma as well as cancer due to the higher possibility of development of invasive carcinomas from adenomas after ER [8, 9, 21]. We also investigated tumor recurrence not only in EGC patients but also in adenoma patients based on our previous report [16].

It is important to evaluate the risk factors of metachronous neoplasm to predict prognosis and determine the follow-up strategy. In previous studies, older age, persistent *H. pylori* infection, and severity of atrophy were associated with a higher risk of metachronous gastric cancer [13–15, 22, 23]. In this study, the significantly higher incidence of metachronous neoplasm was found in patients with synchronous neoplasms, suggesting the importance of meticulous examinations in these patients. Persistent *H. pylori* infection was also associated with increase of metachronous neoplasm which were concordant with previous studies [13–15]. However, the severity of atrophy was not associated with metachronous neoplasm incidence in the present study. This might be caused by the difference in *H. pylori* infection rate and different outcome (adenoma as well as cancer) compared to previous studies [22, 23]. We evaluated the degree of atrophy only with white light image, which is more

![Fig. 3 Metachronous recurrence in the multiple group (n = 182)](image)
associated with higher intra-observer and inter-observer variability than image-enhanced endoscopies like auto-fluorescence image [24].

Our study further strengthened the importance of pathology in multiple neoplasms because the incidence of metachronous cancer was higher in patients with multiple neoplasms including cancer, as shown in Fig. 4b. Therefore, we speculate that patients with multiple gastric neoplasm should have regular meticulous endoscopy follow-up during the follow-up period. Furthermore, we also consider the higher possibility of metachronous gastric cancer in the cancer-included group more than the only adenoma group in multiple gastric neoplasm.

Strict follow-up strategy has several aspects including follow-up interval, examination time of endoscopy, endoscopy methods, and additional considerations. Even though the follow-up interval seems to be the most important among these, there has been no report concerning individualized interval according to risk factors. There is no established guidance on the interval and duration of endoscopic surveillance for recurrence of metachronous gastric cancer [12, 25, 26]. The Japanese guideline recommended annual or biannual endoscopy without specifying the duration [27]. There have been studies suggesting intensive surveillance performed biannually in the first year to detect missed concomitant invasive cancers [25, 28]. In our study, all patients after ER of gastric neoplasm including adenoma were scheduled to be examined with endoscopy biannually at the first year and annually thereafter. The same scheduled examination was performed in patients who were diagnosed to have EGC or adenoma. Considering our results, patients with multiple synchronous gastric neoplasms should have meticulous examination during the follow-up period to find metachronous lesions.

In the aspect of meticulous examination, a few studies have reported the importance of observation time in screening or symptom-based settings [29, 30]. We reported the importance of longer observation time to find possible synchronous lesions [31]. We also investigated the new endoscopic imaging technique, which was related to a higher detection rate of synchronous neoplasms than conventional white-light image endoscopy [32]. Based on the present study, the detection of synchronous neoplasms is important in predicting the risk of metachronous gastric neoplasms. Further studies are needed to address these possibilities.

The exact mechanism of the significantly higher incidence of metachronous recurrence in patients with multiple gastric neoplasms than those with a single lesion remains unclear. This result may be explained by a cancer field effect. The concept of the field effect in cancer is described as a morphologically normal epithelium developing into a tumor as a result of expansion of a genetically abnormal clone or epigenetic alterations, which include hypermethylation of the DNA promoter of certain tumor suppressor genes [33]. This theory has been explored through the association between cancer development and methylation status in the gastric mucosa [34–36]. Patients with multiple gastric cancers had significantly higher methylation levels of cancer-related genes than those with a single gastric cancer [37–39]. The mechanisms of field effect in gastric cancer were explained by the expansion and spread of mutated gastric stem cells. A previous study showed that human gastric body units are clonal, contain multiple multipotential stem cells, and provided definitive evidence for how mutations spread within the human stomach, and how field cancerization develops [40]. However, we do not know the exact mechanism of the development of multiple gastric neoplasms.
There are several limitations to our study. First, we should acknowledge that there was a wide variation of follow-up period (ranging from 12 to 131 months), and that the median follow-up period of 30 months was not long enough for evaluation of metachronous lesions. A further prospective long-term study that assesses the development of metachronous cancer after ER is required to confirm the findings of our study. Second, we did not take multiple samples to evaluate the extent of atrophy. Third, the number of metachronous neoplasm in the subgroup was too small to show a significant difference in recurrence between the cancer-included group and the only adenomas group. Further studies on a larger scale are needed to evaluate the significant difference in recurrence according to the pathology of the multiple group. Finally, this study did not specifically investigate the appropriate follow-up period after ER.

Conclusion

This study showed that patients with synchronous gastric neoplasms, including adenomas, had a higher risk of metachronous neoplasms than patients with a single neoplasm. The incidence of metachronous cancer was higher in subgroups with cancer than subgroups with adenomas only. Therefore, we should consider a strict follow-up strategy with meticulous endoscopic examination in the presence of synchronous neoplasms, especially if cancer is detected in at least one lesion.

Abbreviations

CI: Confidence interval; EGC: Early gastric cancer; EMR: Endoscopic mucosal resection; ESD: Endoscopic submucosal dissection; ER: Endoscopic resection; H. pylori: Helicobacter pylori; HR: Hazard ratio

Acknowledgements

Not Applicable.

Disclosures

There is none to declare.

Authors’ contributions

GYS, HJC and JMP planned and designed the review. GYS and CHJ carried out data collection. Data analysis was performed by GYS and CHL under the supervision of JMP. YKC and MGC supervised the writing of the manuscript. GYS, JMP, YKC and MGC revised the manuscript. All authors reviewed and approved the final draft of the manuscript.

Funding

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Education, Science and Technology (NRF-2017R1D1A1B03035104 and 2019R1A5A2027588) and 2018 Research Fund of the Korean College of Helicobacter and Upper Gastrointestinal Research. These research funds were used to make the study database and analyze the results.

Availability of data and materials

The datasets generated or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

This study was approved by the Institutional Review Board of Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea (IRB number K15RISI0194).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflict of interest.

Received: 1 March 2020 Accepted: 23 June 2020

Published online: 30 June 2020

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–66.
2. Bedikian AY, Chen TT, Kharabian N, Heibrun LK, McBride CM, McMurtrey MJ, Bodey GP. The natural history of gastric cancer and prognostic factors influencing survival. J Clin Oncol. 1984(2):305–10.
3. Jun JK, Choi KS, Lee HY, Suh M, Park B, Song SH, Jung KW, Lee CW, Choi IU, Park EC, et al. Effectiveness of the Korean National Cancer Screening Program in reducing gastric Cancer mortality. Gastroenterology. 2017;152(6):1319–28 e1317.
4. Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, Repici A, Vietti M, De Ceglie A, Amato A, Berr F, Bhandari P, Bialek A, et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2014;47(9):829–54.
5. Committee A50P, Evans JA, Chandrasekhar V, Chatthadi KV, Decker GA, Early DS, Fisher DA, Foley K, Hwang JH, Jue TL, et al. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. Gastrointest Endosc. 2015;82(1):1–8.
6. Goddard AF, Badreldeen R, Pritchard DM, Walker MM, Warren B, British Society of G. The management of gastric polyps. Gut. 2010;59(9):1270–6.
7. de Vries AC, van Gierek NC, Loorman CW, Casparie MK, de Vries E, Meijer GA, Kuipers EJ. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134(4):945–52.
8. Kim YJ, Park JC, Kim JH, Shin SK, Lee SK, Lee YC, Chung JB. Histologic diagnosis based on forceps biopsy is not adequate for determining endoscopic treatment of gastric adenomatous lesions. Endoscopy. 2010;42(8):620–6.
9. Sakurai U, Lauwers GY, Vietti M, Sawabe M, Ariai T, Yoshida T, Aida J, Takubo K. Gastric high-grade dysplasia can be associated with submucosal invasion: evaluation of its prevalence in a series of 121 endoscopically resected specimens. Am J Surg Pathol. 2014;38(11):1545–50.
10. Choi MK, Kim GH, Park DY, Song GA, Kim DJ, Ryu DY, Lee BE, Cheong JG, Cho M. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a single-center experience. Surg Endosc. 2013;27(11):4250–8.
11. Chung IK, Lee JH, Lee SH, Kim SJ, Cho HY, Cho WY, Hwangbo Y, Keum BR, Park JJ, Chun HJ, et al. Therapeutic outcomes in 1000 cases of endoscopic submucosal dissection for early gastric neoplasms: Korean ESD study group multicenter study. Gastrointest Endosc. 2009;69(7):1228–35.
12. Nakajima T, Oda I, Gotoda T, Hatanaka H, Eguchi T, Yokoi C, Saito D. Metachronous gastric cancers after endoscopic resection: how effective is annual endoscopic surveillance? Gastric Cancer. 2006;9(2):193–8.
13. Min BH, Kim ER, Kim KM, Park CK, Lee JH, Rhee PL, Kim JJ. Surveillance strategy based on the incidence and patterns of recurrence after curative endoscopic submucosal dissection for early gastric cancer. Endoscopy. 2015;47(9):784–93.
14. Hahn KY, Park JC, Kim EH, Shin S, Park CH, Chung H, Shin SK, Lee SK, Lee YC. Incidence and impact of scheduled endoscopic surveillance on recurrence after curative endoscopic resection for early gastric cancer. Gastrointest Endosc. 2016;84(4):628–38 e621.
15. Choi II, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B, Nam BH. Helicobacter pylori therapy for the prevention of Metachronous gastric Cancer. N Engl J Med. 2018;378(12):1085–95.
16. Yoon SB, Park JM, Lim CH, Kim JS, Cho YK, Lee BI, Lee IS, Kim SW, Choi MG. Incidence of gastric cancer after endoscopic resection of gastric adenoma. Gastrointest Endosc. 2016;83(6):1176–83.
17. Yoo JH, Shin SJ, Lee KM, Choi JM, Wi JO, Kim DH, Lim SG, Hwang JC, Cheong JY, Yoo BM, et al. How can we predict the presence of missed synchronous lesions after endoscopic submucosal dissection for early gastric cancers or gastric adenomas? J Clin Gastroenterol. 2013;47(2):e17–22.
18. Kim WH, Park CK, Kim YB, Kim YW, Kim HG, Bae HL, Song KS, Chang HK, Chang HJ, Chae YS. A standardized pathology report for gastric Cancer. J Pathol Transl Med. 2009;33(2):106–13.
19. Schleimer RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Davsew SM, Dixon MF, Fenoglio-Preiser CM, Flejou JF, Geboes K, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47(2):251–5.
20. Klima K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1(03):87–97.
21. Choi CW, Kang DH, Park SB, Kim S, Cho M. Endoscopic submucosal dissection as a treatment for gastric adenomatous polyps: predictive factors for early gastric cancer. Scand J Gastroenterol. 2012;47(10):1218–25.
22. Hanaoka N, Uedo N, Shiotsui A, Inoue T, Takeuchi Y, Higashino K, Ishihara R, Ishi H, Haruma K, Tatsuta M, Autofluorescence imaging for predicting development of metachronous gastric cancer after helicobacter pylori eradication. J Gastroenterol Hepatol. 2010;25(12):1844–9.
23. Mori G, Nakajima T, Asada K, Shimazu T, Yamamichi N, Maekita T, Yoko C, Fujishiro M, Gotoda T, Ichinose M, et al. Incidence of and risk factors for metachronous gastric cancer after endoscopic resection and successful helicobacter pylori eradication: results of a large-scale, multicenter cohort study in Japan. Gastric Cancer. 2016;19(3):911–8.
24. Inoue T, Uedo N, Ishihara R, Kawaguchi T, Kawada N, Chatani R, Kizu T, Tamai C, Takeuchi Y, Higashino K, et al. Autofluorescence imaging videodendoscopy in the diagnosis of chronic atrophic fundal gastritis. J Gastroenterol. 2010;45(1):45–51.
25. Kato M, Nishida T, Yamamoto K, Hayashi S, Kitamura S, Yabuta T, Yoshio T, Nakamura T, Komori M, Kawai N, et al. Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: a multicentre retrospective cohort study by Osaka University ESD study group. Gut. 2013;62(10):1425–32.
26. Sekiguchi M, Sugiyama M, Oda I, Abe S, Nonaka S, Yoshinaga S, Taniguchi H, Sekine S, Kusuda T, Saito Y. Favorable long-term outcomes of endoscopic submucosal dissection for locally recurrent early gastric cancer after endoscopic resection. Endoscopy. 2013;45(9):708–13.
27. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–91.
28. Nishida T, Tsuji M, Kato M, Hayashi Y, Akasaka T, Iijima H, Takehara T. Endoscopic surveillance strategy after endoscopic resection for early gastric cancer. World J Gastrointest Pathophysiol. 2014;5(2):100–6.
29. Lee HH, Park JM, Lim CH, Kim JS, Cho YK, Choi MG. The impact of pre-resection endoscopic examination time on the rate of synchronous gastric neoplasms missed during endoscopic treatment. Surg Endosc. 2017;31(10):3952–60.
30. Gweon TG, Park JM, Lim CH, Kim JS, Cho YK, Kim SW, Choi MG. Trimodal imaging endoscopy reduces the risk of synchronous gastric neoplasia. Eur J Gastroenterol Hepatol. 2015;27(9):215–20.
31. Kocherhead P, Chan AT, Nishihara R, Fuchs CS, Beck AH, Giovannucci E, Ogino S. Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol. 2015;28(1):14–29.
32. Nakajima T, Maekita T, Oda I, Gotoda T, Yamamoto S, Umemura S, Ichinose M, Sugimura T, Ushijima T, Saito D. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomark Prev. 2006;15(11):2317–23.
33. Lee HH, Park JM, Lim CH, Kim JS, Cho YK, Choi MG. Etiologic field effect for early gastric cancer. Gastroenterol Hepatol. 2015;13(3):480–7 e482.
34. Lee HH, Park JM, Lim CH, Kim JS, Cho YK, Kim SW, Choi MG. Trimodal imaging endoscopy reduces the risk of synchronous gastric neoplasia. Eur J Gastroenterol Hepatol. 2015;27(9):215–20.
35. Ando T, Yoshida T, Enomoto S, Asada K, Tatematsu M, Ichinose M, Sugiyama T, Ushijima T. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer. 2009;124(10):2367–74.
36. Nakajima T, Nakawara K, Hiyama T, Yamanaka T, Soda H, Suzuki H, Kajiyama Y, Fujimoto Y, Nishihara R, Fuchs CS, et al. Concurrent hypermethylation of multiple tumor-related genes in gastric carcinoma and adjacent normal tissues. Cancer. 2001;91(12):2294–301.
37. Miyoshi E, Haruma K, Hiyama T, Tanaka S, Yoshihara M, Shimamoto F, Chataya K. Microsatellite instability is a genetic marker for the development of multiple gastric cancers. Int J Cancer. 2001;95(6):350–3.
38. Sakata K, Tamura G, Endoh Y, Ohmura K, Ogata S, Motoyama T. Hypermethylation of the hMLH1 gene promoter in solitary and multiple gastric cancers with microsatellite instability. Br J Cancer. 2002;86(4):564–7.
39. McDonald SA, Greaves LC, Gutierrez-Gonzalez I, Rodriguez-Justo M, Deheragoda M, Leedham SJ, Taylor RW, Lee CY, Preston SL, Lovell M, et al. Mechanisms of field cancerization in the human stomach: the expansion and spread of mutated gastric stem cells. Gastroenterology. 2008;134(2):500–10.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions